Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tipifarnib and Gemcitabine in Metastatic Breast Cancer
NCT00100750Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2005
- Primary completion
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tipifarnib in breast cancer, sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate up to 9 years. Started Sep 2005; status: completed.
02
Drugs
tipifarnib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00100750.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00100750.